Tag: GWPH

GW Pharma Raises $300 Million at $158 per Share

GW Pharmaceuticals plc Announces Pricing of Public Offering of ADSs Raising Gross Proceeds of $300 Million LONDON and CARLSBAD, Calif., Oct. 02, 2018 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc...
- October 2nd, 2018 at 8:48 pm

GW Pharma to Raise $300 Million

GW Pharmaceuticals Announces Proposed Public Offering of ADSs LONDON and CARLSBAD, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”),...
- October 1st, 2018 at 4:19 pm

Global Cannabis Stocks Extend Rally in September

Cannabis stocks, as measured by the Global Cannabis Stock Index, added to their August gains in September, rising 2.4% to 114.83: The index, which had 53 qualifying members that were...
- September 30th, 2018 at 11:17 am

GW Pharma Reveals Epidiolex Pricing

GW Pharmaceuticals (NASDAQ: GWPH) released financials for its fiscal 2018 Q3 after the close today and hosted a conference call for investors and analysts. Readers can access a full...
- August 7th, 2018 at 11:24 pm

Global Cannabis Stocks Suffer Slight Decline in May

Cannabis stocks, as measured by the Global Cannabis Stock Index, fell slightly again in May, declining 2.3% to 104.89, after advancing in the first part of the month and then pulling back:...
- June 1st, 2018 at 1:15 pm

Global Cannabis Stock Index Declines 0.5% in April

Cannabis stocks, as measured by the Global Cannabis Stock Index, fell slightly in April, declining 0.5% to 107.33, after bouncing twice near 95 early in the month: The index, which went through...
- May 1st, 2018 at 1:03 pm

GW Pharma Epidiolex FDA Decision Date Set for June 27th

GW Pharmaceuticals Announces Acceptance of NDA Filing for Epidiolex(R) (cannabidiol) in the treatment of Lennox-Gastaut syndrome and Dravet syndrome LONDON and CARLSBAD, Calif., Dec. 28, 2017 (GLOBE NEWSWIRE) —...
- December 28th, 2017 at 7:25 am

GW Pharma Closes $317.4 Million Equity Offering

GW Pharmaceuticals plc Announces the Closing of Public Offering of ADSs Raising Gross Proceeds of $317.4 Million and Full Exercise of Underwriter’s Option to Purchase Additional ADSs LONDON, UK,...
- December 12th, 2017 at 6:37 am

GW Pharma to Raise up to $258.75 Million in Underwritten Deal

GW Pharmaceuticals Announces Proposed Public Offering of ADSs LONDON, Dec. 05, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (GWPRF) (Nasdaq:GWPH) (“GW” or the “Company”), a biopharmaceutical company focused on...
- December 5th, 2017 at 4:38 pm

GW Pharma Expects FDA Decision on Epidiolex in Mid-2018

GW Pharmaceuticals plc Reports Fiscal Fourth Quarter 2017 and Year-End Financial Results and Operational Progress Epidiolex® (cannabidiol) NDA Submitted to FDA Conference call today at 7:30 a.m. EST LONDON...
- December 4th, 2017 at 7:42 am